江苏澳洋健康产业股份有限公司 2025 年半年度报告全文 江苏澳洋健康产业股份有限公司 2025 年半年度报告 2025 年 8 月 1 江苏澳洋健康产业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人沈学如、主管会计工作负责人李霞及会计机构负责人(会计主 管人员)李霞声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本半年度报告涉及未来计划及经营目标等前瞻性陈述，不构成公司对投资 者的实质承诺，投资者及相关人士均应当对此保持足够的风险认识，并且应 当理解计划、预测与承诺之间的差异。 公司存在国家政策对医疗健康产业影响等风险，敬请广大投资者注意投资 风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | . | DK | | --- | --- | | 1 | | | 第二节 | 公司简介和主要财务指标 6 | | --- | --- | | 第三节 | ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a decline in revenue and profit, alongside a high PE ratio compared to industry averages [1][2] - As of August 25, Aoyang Health's stock closed at 4.27 yuan, down 2.06%, with a rolling PE ratio of 115.45 times and a total market capitalization of 3.27 billion yuan [1] - The average PE ratio for the healthcare service industry is 50.60 times, with a median of 64.30 times, placing Aoyang Health at the 38th position in the industry ranking [1][2] Group 2 - For the first quarter of 2025, Aoyang Health reported an operating income of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.49 million yuan, down 39.82% [2] - The company's sales gross margin stands at 15.09% [2] - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and net profit in the first quarter of 2025 compared to the previous year [1][2] - Aoyang Health's closing stock price on August 22 was 4.36 yuan, down 1.80%, with a rolling PE ratio of 117.88 times, and a total market capitalization of 3.339 billion yuan [1] - The average PE ratio for the healthcare service industry is 49.39 times, with a median of 62.33 times, placing Aoyang Health at the 39th position within the industry [1][2] Group 2 - For the first quarter of 2025, Aoyang Health reported an operating income of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% year-on-year, with a sales gross margin of 15.09% [2] - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - Aoyang Health's main business includes medical services, pharmaceutical distribution, and biotechnology, with key products being medical services and pharmaceutical logistics [1]

Group 1 - The high-pressure oxygen chamber concept sector experienced a decline of 0.76%, ranking among the top declines in concept sectors as of the market close on August 22 [1] - Within the sector, major declines were observed in companies such as Samsung Medical, Aoyang Health, and Dahu Co., with notable increases in Hangyang Co., Yinkang Life, and International Medicine, which rose by 0.97%, 0.86%, and 0.37% respectively [1] Group 2 - The high-pressure oxygen chamber concept sector saw a net outflow of 260 million yuan in principal funds today, with six stocks experiencing net outflows [2] - The stock with the highest net outflow was Tiedao Heavy Industry, which had a net outflow of 143 million yuan, followed by Innovative Medical, Samsung Medical, and Aoyang Health with net outflows of 60.83 million yuan, 43.65 million yuan, and 13.12 million yuan respectively [2] - Conversely, the stocks with the highest net inflows included International Medicine, Jinling Pharmaceutical, and Yinkang Life, with net inflows of 3.35 million yuan, 3.27 million yuan, and 3.20 million yuan respectively [2]

Group 1 - As of August 21, 2025, Aoyang Health's stock price closed at 4.44 yuan, an increase of 0.16 yuan, representing a rise of 3.74% from the previous trading day [1] - The stock opened at 4.29 yuan, reached a high of 4.55 yuan, and a low of 4.27 yuan, with a trading volume of 829,827 hands and a transaction amount of 368 million yuan [1] - Aoyang Health operates in the healthcare services sector, with business areas including medical health services, pharmaceutical distribution, hair medical services, assisted reproduction, and medical beauty [1] Group 2 - On the morning of August 21, Aoyang Health experienced a rapid pullback, with a drop of over 2% within five minutes, reaching a low of 4.4 yuan and a transaction amount of 65.59 million yuan [1] - In terms of capital flow, on August 21, the net inflow of main funds was 23.03 million yuan, with a cumulative net inflow of 24.78 million yuan over the past five trading days [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - Aoyang Health's stock closed at 4.44 yuan, with a PE ratio of 120.04, marking a new low in 48 days, and a total market capitalization of 3.4 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with its main products being medical services and pharmaceutical logistics [1] Group 2 - In the first quarter of 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.49 million yuan, down 39.82% [2] - The average PE ratio for the medical services industry is 49.07, with a median of 65.74, positioning Aoyang Health at 39th place within the industry [1][2] - The company has received various honors, including being ranked 32nd in the non-public hospital top 100 list and second among county-level non-public hospitals in China [1]

Group 1 - The high-pressure oxygen chamber concept declined by 0.68%, ranking among the top declines in concept sectors as of the market close on August 20 [1] - Within the high-pressure oxygen chamber sector, companies such as Innovate Medical, Yinkang Life, and Aoyang Health experienced significant declines, while Iron Construction Heavy Industry, Samsung Medical, and Dahu Co. saw increases of 4.29%, 1.08%, and 0.89% respectively [1] - The high-pressure oxygen chamber sector experienced a net outflow of 444 million yuan in main funds, with Innovate Medical leading the outflow at 537 million yuan [2] Group 2 - The top gainers in the market included the Tonghuashun Fruit Index at 3.70%, AI mobile phones at 2.77%, and MCU chips at 2.60%, while the high-pressure oxygen chamber concept was among the top decliners [2] - The main funds saw significant outflows from several stocks in the high-pressure oxygen chamber sector, with Innovate Medical, Aoyang Health, and Dahu Co. being the most affected [2] - Conversely, Iron Construction Heavy Industry, Samsung Medical, and Jinling Pharmaceutical attracted net inflows of main funds, indicating a shift in investor interest [2]

Group 1 - The core viewpoint of the article highlights the growth potential of China's chemical fiber industry, with a projected production increase of 4.7% year-on-year by June 2025, reaching 7.36 million tons [1] - In the first half of 2025, China's cumulative chemical fiber production is expected to be 42.36 million tons, reflecting a cumulative growth of 4.9% [1] - The article references a report by Zhiyan Consulting that analyzes the market operation status and investment prospects of the chemical fiber industry from 2025 to 2031 [1] Group 2 - Listed companies in the chemical fiber sector include Xinxiang Chemical Fiber, Hengli Petrochemical, Huafeng Superfiber, Rongsheng Petrochemical, Jilin Chemical Fiber, Tongkun Co., Zhongtai Chemical, Nanjing Chemical Fiber, Taihe New Materials, and Aoyang Health [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [2]

Group 1 - The core viewpoint of the article highlights the growth potential of China's synthetic fiber industry, with a projected production increase of 4.5% year-on-year by June 2025, reaching 6.75 million tons [1] - In the first half of 2025, China's cumulative synthetic fiber production is expected to reach 38.901 million tons, reflecting a cumulative growth of 5% [1] - The article references several listed companies in the synthetic fiber sector, including Hengyi Petrochemical, Rongsheng Petrochemical, and Xin Fengming, indicating a focus on key players in the industry [1] Group 2 - The report titled "2025-2031 China Synthetic Fiber Industry Market Status Survey and Development Trend Analysis" by Zhiyan Consulting provides insights into the market dynamics and future trends of the synthetic fiber industry [1] - Zhiyan Consulting is recognized as a leading industry consulting firm in China, specializing in comprehensive industry research and providing tailored consulting services [2] - The data utilized in the article is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting, ensuring reliability and accuracy [3]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Aoyang Health, indicating a significant decline in revenue and profit compared to the previous year [1][2] - As of August 19, Aoyang Health's stock closed at 4.29 yuan, with a 2.88% increase, and a rolling PE ratio of 115.99, marking a new low in 46 days, with a total market value of 3.285 billion yuan [1] - The average PE ratio for the healthcare service industry is 49.81, with a median of 65.60, placing Aoyang Health at the 38th position within the industry [1] Group 2 - For Q1 2025, Aoyang Health reported an operating income of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82%, with a gross profit margin of 15.09% [2] - The company operates in medical services, pharmaceutical distribution, and biotechnology, with key products including medical services and pharmaceutical logistics [1] - Aoyang Health has received various honors, including being ranked 32nd in the non-public hospital top 100 list and second among county-level non-public hospitals in China [1]